trovafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibacterials, nalidixic acid derivatives	2777	147059-72-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trovafloxacin trovafloxacin mesylate trovafloxacin mesilate trovafloxacin acid	a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity Molecular weight: 416.36 Formula: C20H15F3N4O3 CLOGP: -1.47 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 99.76 ALOGS: -3.77 ROTB: 3 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trovafloxacin
trovafloxacin mesylate
trovafloxacin mesilate
trovafloxacin acid

a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity

Molecular weight: 416.36
Formula: C20H15F3N4O3
CLOGP: -1.47
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 99.76
ALOGS: -3.77
ROTB: 3

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O
0.20	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	91 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.24 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	26 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 18, 1997	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01MA13	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D059005	Topoisomerase II Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50908	agente hepatotoxico
CHEBI has role	CHEBI:53559	topoisomerase IV inhibitors
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infection due to Pseudomonas aeruginosa	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Staphylococcal pneumonia	indication	22754005
Acute gonococcal urethritis	indication	29864006
Acute bacterial peritonitis	indication	31860008
Postoperative infection	indication	33910007
Pneumonia due to Streptococcus	indication	34020007
Pneumonia due to Pseudomonas	indication	41381004
Gonorrhea of rectum	indication	42746002
Pneumonia due to Mycoplasma pneumoniae	indication	46970008
Pneumonia due to Escherichia coli	indication	51530003
Acute gonococcal endometritis	indication	65295003	DOID:7527
Miscarriage with sepsis	indication	67465009
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Acute bacterial sinusitis	indication	75498004
Endomyometritis	indication	88027004
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Postnatal infection	indication	178280004
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Chlamydial pelvic inflammatory disease	indication	188463006
Acute Moraxella catarrhalis bronchitis	indication	195722003
Acute bacterial bronchitis	indication	233598009
Chlamydial pneumonia	indication	233609002
Female pelvic cellulitis	indication	280486004
Streptococcal Septic Abortion	indication
Complicated Klebsiella Peritonitis	indication
Complicated E. Coli Peritonitis	indication
Enterococcus Endomyometritis	indication
Complicated Streptococcus Peritonitis	indication
Complicated Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Complicated Bacteroides Peritonitis	indication
Prevotella Postpartum Infection	indication
Gardnerella Endomyometritis	indication
Gardnerella Postpartum Infection	indication
Peptostreptococcus Pelvic Cellulitis	indication
Prevotella Septic Abortion	indication
Bacteroides Septic Abortion	indication
E. Coli Endomyometritis	indication
Colorectal Surgery Infection Prevention	indication
Vaginal Hysterectomy Infection Prevention	indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea	indication
Chronic Bacterial Prostatitis	indication
Haemophilus Parainfluenzae Bronchitis	indication
Haemophilus Influenzae Bronchitis	indication
Streptococcus Pneumoniae Bronchitis	indication
Staphylococcus Aureus Bronchitis	indication
Chlamydia Cervicitis	indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection	indication
Moraxella Catarrhalis Pneumonia	indication
Streptococcal Endomyometritis	indication
Peptostreptococcus Postpartum Infection	indication
Legionella Pneumophila Pneumonia	indication
Peptostreptococcus Septic Abortion	indication
Streptococcal Postpartum Infection	indication
E. Coli Pelvic Cellulitis	indication
E. Coli Postpartum Infection	indication
Enterococcus Postpartum Infection	indication
E. Coli Septic Abortion	indication
Peptostreptococcus Endomyometritis	indication
Gardnerella Septic Abortion	indication
Prevotella Endomyometritis	indication
Complicated Bacterial Peritonitis	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Prevotella Pelvic Cellulitis	indication
Streptococcal Pelvic Cellulitis	indication
Bacteroides Postpartum Infection	indication
Gardnerella Pelvic Cellulitis	indication
Enterococcus Pelvic Cellulitis	indication
Complicated Skin and Skin Structure Proteus Infection	indication
Enterococcus Septic Abortion	indication
Complicated Skin and Skin Structure E. Coli Infection	indication
Bacteroides Pelvic Cellulitis	indication
Bacteroides Endomyometritis	indication
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.92	acidic
pKa2	8.56	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	4.31	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	5.40	DRUG MATRIX
Topoisomerase IV	Enzyme		PARC_ECOLI PARE_ECOLI	INHIBITOR			CHEMBL	CHEMBL
DNA gyrase	Enzyme		GYRA_ECOLI GYRB_ECOLI	INHIBITOR			CHEMBL	CHEMBL

External reference:

ID	Source
4024108	VUID
N0000022113	NUI
D02123	KEGG_DRUG
147059-75-4	SECONDARY_CAS_RN
4021091	VANDF
4024108	VANDF
C0379881	UMLSCUI
CHEBI:9763	CHEBI
TR6	PDB_CHEM_ID
CHEMBL428	ChEMBL_ID
DB00685	DRUGBANK_ID
C080163	MESH_SUPPLEMENTAL_RECORD_UI
62959	PUBCHEM_CID
7370	INN_ID
9F388J00UK	UNII
115552	RXNORM
5646	MMSL
7888	MMSL
d04263	MMSL
007320	NDDF
007321	NDDF
116542007	SNOMEDCT_US
371322001	SNOMEDCT_US
96092008	SNOMEDCT_US
CHEMBL1200779	ChEMBL_ID

Pharmaceutical products:

None